12 Lung Cancer Clinical Trials in Fullerton, CA (2026)

Q: How do I join a clinical trial in Fullerton?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Fullerton research site will contact you.

Recruiting Lung Cancer Studies in Fullerton

NCT04389632Recruiting

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

This trial will look at a drug called sigvotatug vedotin (SGN-B6A) alone and with pembrolizumab, with or without chemotherapy, to find out whether it is safe for people who have solid tumors. It will ...

Fullerton, CAPHASE11,006 participantsSeagen, a wholly owned subsidiary of Pfizer

View Study Details

NCT06216301Recruiting

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based...

Fullerton, CAPHASE3734 participantsNovoCure GmbH

View Study Details

NCT06758401Recruiting

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCL...

Fullerton, CAPHASE3714 participantsPfizer

View Study Details

NCT06623422Recruiting

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want ...

Fullerton, CAPHASE3680 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06875310Recruiting

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemothera...

Fullerton, CAPHASE3630 participantsMirati Therapeutics Inc.

View Study Details

NCT06203210Recruiting

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

This study was designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung cancer (SCLC)....

Fullerton, CAPHASE3540 participantsDaiichi Sankyo

View Study Details

NCT06667076Recruiting

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth f...

Fullerton, CAPHASE2480 participantsJanssen Research & Development, LLC

View Study Details

NCT07005128Recruiting

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

The main objective of the study is to compare the efficacy of tarlatamab in combination with durvalumab, carboplatin and etoposide to the combination of durvalumab, carboplatin and etoposide on prolon...

Fullerton, CAPHASE3330 participantsAmgen

View Study Details

NCT06772623Recruiting

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide. The purpose of this study is to as...

Fullerton, CAPHASE1252 participantsAbbVie

View Study Details

NCT07227298Recruiting

Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

This study is being done to learn more about a new medicine called PF-08634404 and how it works when used with other cancer medicines in people who have advanced solid tumors. An advanced solid tumor ...

Fullerton, CAPHASE1162 participantsPfizer

View Study Details

NCT07140016Recruiting

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

Genes give your body instructions on how to make proteins. Proteins are needed to keep the body working properly. Many types of cancer are caused by changes in certain genes, making them faulty. Some ...

Fullerton, CAPHASE140 participantsAstellas Pharma Global Development, Inc.

View Study Details

NCT05271292Recruiting

Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.

This is a Phase 1b/2, single-arm, open-label, dose-escalation study including 2 stages: Phase 1b: Dose-Escalation Stage (Single-Dose and Consecutive-Dose Periods) Phase 2: recommended Phase 2 dose (...

Fullerton, CAPHASE136 participantsChipscreen Biosciences, Ltd.

View Study Details

About Lung Cancer Clinical Trials in Fullerton

Lung cancer is the leading cause of cancer death worldwide, starting in the cells of the lungs. The two main types are non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Treatments include surgery, chemotherapy, radiation, immunotherapy, and targeted drugs.

There are currently 12 lung cancer clinical trials recruiting participants in Fullerton, CA. These studies are seeking a combined 5,604 participants. Research is being sponsored by Seagen, a wholly owned subsidiary of Pfizer, NovoCure GmbH, Pfizer and 8 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Lung Cancer Clinical Trials in Fullerton — FAQ

Are there lung cancer clinical trials in Fullerton?

Yes, there are 12 lung cancer clinical trials currently recruiting in Fullerton, CA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Fullerton?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Fullerton research site will contact you about next steps.

Are clinical trials in Fullerton free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Fullerton studies also compensate for your time and travel.

What lung cancer treatments are being tested?

The 12 active trials in Fullerton are testing new therapies including novel drugs, biologics, and treatment approaches for lung cancer.

Data updated July 17, 2026 from ClinicalTrials.gov